Immunotherapy for advanced GI cancers with specific tumor markers
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests an immune-based treatment for advanced (Stage III–IV) GI cancer. You may be able to join only if your tumor shows certain “marker” proteins on special lab staining, and your blood and organ tests meet study limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent before any study testing starts.
- Your tumor tissue must test positive for at least one specific cancer “marker” (antigen) from a listed set like GD2, mesothelin, CEA, P16, or several others.
- Your cancer must be confirmed as high-risk Stage III–IV FIGO, and you should be able to follow the study plan.
- Your health status should be fairly good (ECOG score 0, 1, or 2) and you should have at least 3 months of expected life.
- Your blood counts and kidney/liver tests must be adequate (enough neutrophils and platelets; limits on bilirubin, AST/ALT, creatinine, and other liver/kidney measures).
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This trial tests a new treatment using your own immune cells that are trained to attack cancer. It is for people with advanced stomach, colon, or esophageal cancer who have already tried other treatments that didn't work.
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
This trial tests a treatment that takes immune cells from your tumor, multiplies them in a lab, and gives them back to you to fight the cancer. It is for people with advanced solid tumors who have tried other treatments or cannot have them.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests GC101 tumor-infiltrating lymphocytes (TILs), which are special immune cells collected from a tumor, grown in a lab, and given back to treat gastrointestinal cancers that have returned or spread. It may help your immune system better attack the cancer, especially when standard treatments have not worked.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.